Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876187 · ClinicalTrials.gov registry record · Phase 2
A Study of Tanezumab in Adults With Chronic Low Back Pain
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,359
- Enrollment target
NCT00876187: Completed Phase 2 study, sponsored by Pfizer.
NCT00876187 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,359 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (922% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00876187, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,359 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.
Primary Outcome
Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to a
Interventions
- BIOLOGICAL Tanezumab 20 mg IV
- DRUG Placebo for naproxen
- BIOLOGICAL Tanezumab 10 mg IV
- BIOLOGICAL Tanezumab 5 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,359 participants |
| Start Date | 2009-06-15 |
| Est. Completion | 2011-02-01 |
| Phase | Phase 2 |
What the finished NCT00876187 record still lists
NCT00876187 is an interventional study that assigns participants to a tested intervention. Its 1,359 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (922% higher).
The record links to 0 conditions, and to 4 interventions - of which Tanezumab 20 mg IV is the first listed.
NCT00876187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00876187 about?
NCT00876187 is a clinical study titled "A Study of Tanezumab in Adults With Chronic Low Back Pain". The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.
What is the current status of trial NCT00876187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,359 participants. The study started on 2009-06-15. Estimated completion is 2011-02-01.
What interventions are being tested in trial NCT00876187?
The interventions under investigation include: Tanezumab 20 mg IV (BIOLOGICAL), Placebo for naproxen (DRUG), Tanezumab 10 mg IV (BIOLOGICAL), Tanezumab 5 mg IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT00876187?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00876187's enrollment target sits among peer trials
1,359 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI